# Echinaforce COVID-19 Shedding Study

> **NCT04999098** · PHASE4 · TERMINATED · sponsor: **A. Vogel AG** · enrollment: 40 (actual)

## Conditions studied

- COVID-19 Respiratory Infection
- SARS-CoV2 Infection

## Interventions

- **DRUG:** Echinaforce Forte tablets
- **DRUG:** Echinaforce Chewable tablets
- **DRUG:** Echinaforce tincture

## Key facts

- **NCT ID:** NCT04999098
- **Lead sponsor:** A. Vogel AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-15
- **Primary completion:** 2023-05-15
- **Final completion:** 2023-08-15
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** insufficient recruitment
- **Last updated:** 2024-08-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04999098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04999098, "Echinaforce COVID-19 Shedding Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04999098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*